Price
$254.76+31.99%1Y
1M+8.90%1Y+31.99%
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Average5/10
Value9
Quality95
Momentum47
Growth58
P/E (TTM)114.4
Market Cap$382.49B
1Y Return+31.99%
5Y Return+145.25%
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $11.43B (-6.40%)
●Vyalev grew +1383.33% YoY●HUMIRA -52.02% YoY
SegmentLatestQoQYoY
- SKYRIZI$3.77B-7.59%+29.33%
- RINVOQ$1.41B-9.88%+15.16%
- Other Products$1.02B+55.30%-18.20%
- Vraylar$902.0M-3.11%+18.22%
- Botox Therapeutic$842.0M+2.06%+16.46%
- Botox Cosmetic$371.0M-2.11%+25.76%
- Creon$361.0M-1.90%+1.69%
- HUMIRA$357.0M-42.33%-52.02%
- VENCLEXTA$341.0M0.00%+9.29%
- Imbruvica$332.0M-34.52%-37.24%
- Ubrelvy$330.0M-4.07%+41.63%
- Linzess Constella$272.0M-13.65%+95.68%
- Qulipta$250.0M-0.79%+45.35%
- Other Aesthetics$248.0M-6.42%-8.15%
- MAVYRET$183.0M+25.34%+28.87%
- Elahere$160.0M+6.67%-3.03%
- Vyalev$89.0M+67.92%+1383.33%
- Juvederm Collection$85.0M-13.27%+13.33%
- Other Neuroscience$46.0M+9.52%-38.67%
- Epkinly$32.0M+28.00%+113.33%
- Other Oncology$24.0M+118.18%-
- Alphagan Combigan---
- Duodopa---
- Lumigan Ganfort---
- Other Eye Care---
- Ozurdex---
- Restasis---